Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.33 |
| ▸ | NPY1R | P25929 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 2/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | GLP1R | P43220 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572335 | 0.90 | NPY1R (0.31) | NPY4RNPY1R | |
| SCHEMBL20094872 | 0.81 | — | — | |
| SCHEMBL11727564 | 0.81 | USP2 (0.37) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL16572076 | 0.78 | SIRT6 (0.37) | TLR2SIRT6SIRT1 | |
| SCHEMBL16627709 | 0.75 | SPHK1 (0.43) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL16572314 | 0.75 | SPHK1 (0.43) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL25603967 | 0.73 | MEN1 (0.31) | — | |
| SCHEMBL19750583 | 0.72 | KDM4E (0.42) | — | |
| SCHEMBL1344935 | 0.71 | C3AR1 (0.38) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11737292 | 0.70 | C3AR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267649-A1 | STABLE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267649-A1 | STABLE SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, CACNA1B | NPY4R 1088/4885NPY1R 1090/4885TLR2 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.